Results for berman's center position paper translation from Spanish to English

s&d position paper - 12 april 2011.
s&d position paper - 12 april 2011.

position paper on the limits of genotoxic impurities
position paper on the limits of genotoxic impurities

oxfam international position paper. oxford, reino unido.
oxfam international position paper. oxford, uk.

título del documento position paper on compliance with pharmacovigilance regulatory obligations
position paper on compliance with pharmacovigilance regulatory obligations

efforts to facilitate asset recovery: position paper submitted by indonesia
efforts to facilitate asset recovery: position paper submitted by indonesia

position paper on voting in the framework of the discussion and adoption of cpmp opinions
position paper on voting in the framework of the discussion and adoption of cpmp opinions

position paper on re-establishment of working seeds and working cell banks using tse compliant materials
position paper on re-establishment of working seeds and working cell banks using tse compliant materials

position paper on the non-clinical safety studies to support clinical trials with a single low dose of a compound
note for guidance on photosafety testing

concept paper on the development of a cpmp position paper on the non-clinical safety studies to support low dose clinical screening studies in humans
concept paper on the development of a cpmp position paper on the non-clinical safety studies to support low dose clinical screening studies in humans

título del documento position paper on compliance with pharmacovigilance regulatory obligations concept paper on the development of a cpmp note for guidance on the use of medicinal products during pregnancy:
document title position paper on compliance with pharmacovigilance regulatory obligations concept paper on the development of a cpmp note for guidance on the use of medicinal products during pregnancy:

tengo el honor de transmitirle en el anexo adjunto el position paper of the chinese government on the outlawing of the falun gong organization (véase el anexo).
i have the honour to transmit herewith the position paper of the chinese government on the outlawing of the falun gong organization (see annex).

por lo tanto se concluyó, de acuerdo con su reciente " position paper " sobre excipientes farmacológicamente activos, que no se requería el establecimiento de un lmr para esta sustancia.
it therefore concluded, in accordance with its recent position paper on pharmacologically active excipients, that an mrl was not required to be established for this substance.

safety and supply of plasma-derived medicinal products note for guidance on pharmaceutical aspects of the product literature for human vaccines position paper on re-establishment of working seeds and working cell banks using tse compliant materials
safety and supply of plasma-derived medicinal products position paper on re-establishment of working seeds and working cell banks using tse compliant materials note for guidance on the use of bovine serum in the manufacture of human biological medicinal products points to consider on quality aspects of medicinal products containing active substances produced by stable transgene experession in higher plants note for guidance on pharmaceutical aspects of the product literature for human vaccines

título del documento revision of note for guidance on the conduct of pharmacovigilance for centrally authorised products revision of crisis management plan regarding centrally authorised products for human use guidance document for the implementation of the position paper on compliance with pharmacovigilance regulatory obligations contribution to note for guidance on the use of medicinal products during pregnancy:
document title revision of note for guidance on the conduct of pharmacovigilance for centrally authorised products revision of crisis management plan regarding centrally authorised products for human use guidance document for the implementation of the position paper on compliance with pharmacovigilance regulatory obligations contribution to note for guidance on the use of medicinal products during pregnancy:

esta es la razón que explica y motiva la cita incluida en el presente documento de una parte sustancial de su “position paper i”, que había preparado como introducción a los trabajos del grupo de estudio y que debe de haber sido uno de sus últimos escritos.
this fully explains and warrants the quotation here of a substantial part of his "position paper i" in the appendix; this paper was prepared as an introduction to the work leading up to this opinion, and must have been one of the last pieces he wrote.

título del documento position paper on the non-clinical safety studies to support clinical trials with a single low dose of a compound note for guidance on specification limits for residues of metal catalysts note for guidance on comparability of medicinal products containing biotechnology-derived proteins as drug substance:
medicinal products in patients with hepatic impairment note for guidance on clinical investigation of medicinal products

46/63 grupo de trabajo del cpmp " eficacia "título del documento note for guidance on clinical investigation of medicinal products for the treatment of diabetes mellitus note for guidance on clinical investigation of anti-depressive agents note for guidance on clinical investigation of medicinal products for pain treatment position paper on new modified formulations of acetyl salicylic acid in the secondary prevention of cardiovascular events note for guidance on clinical investigation of medicinal products for treatment of peripheral arterial occlusive disease concept paper on the revision of the note for guidance on evaluation of new anti-bacterial medicinal product (cpmp/ewp/558/95) and the note for guidance on the pharmacodynamic section of the summary of product characteristics for antibacterial products points to consider on biostatistical/methodological issues arising from cpmp discussion on licensing applications:
emea 2002 emea/mb/049/01-en-finalwork progamme for 2002 cpmp efficacy working party document title note for guidance on clinical investigation of medicinal products for the treatment of diabetes mellitus note for guidance on clinical investigation of anti-depressive agents note for guidance on clinical investigation of medicinal products for pain treatment position paper on new modified formulations of acetyl salicylic acid in the secondary prevention of cardiovascularpage 45/62events note for guidance on clinical investigation of medicinal products for treatment of peripheral arterial occlusive disease concept paper on the revision of the note for guidance on evaluation of new anti-bacterial medicinal product (cpmp/ewp/558/95) and the note for guidance on the pharmacodynamic section of the summary of product characteristics for antibacterial products points to consider on biostatistical/methodological issues arising from cpmp discussion on licensing applications: